Health Care [ 12/12 ] | Health Care Equipment & Supplies [ 43/74 ]
NASDAQ | Common Stock
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products.
In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices.
Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.
It sells its products through direct sales, service forces, independent distributors, and sales representatives.
Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 29, 24 | 1.06 Increased by +13.98% | 1.02 Increased by +3.92% |
| May 2, 24 | 1.03 Decreased by -2.83% | 0.98 Increased by +5.10% |
| Feb 1, 24 | 0.98 Decreased by -8.41% | 0.95 Increased by +3.16% |
| Nov 9, 23 | 0.89 Increased by +8.54% | 0.84 Increased by +5.95% |
| Jul 31, 23 | 0.93 Decreased by -2.11% | 0.89 Increased by +4.49% |
| May 1, 23 | 1.06 Decreased by -48.79% | 0.88 Increased by +20.45% |
| Feb 1, 23 | 1.07 Decreased by -50.69% | 0.91 Increased by +17.58% |
| Oct 31, 22 | 0.82 Decreased by -49.07% | 0.62 Increased by +32.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 987.90 M Increased by +4.51% | 178.60 M Increased by +97.13% | Increased by +18.08% Increased by +88.63% |
| Jun 30, 24 | 1.01 B Increased by +2.74% | 194.50 M Increased by +580.25% | Increased by +19.23% Increased by +567.43% |
| Mar 31, 24 | 1.02 B Decreased by -0.85% | 169.90 M Decreased by -22.24% | Increased by +16.69% Decreased by -21.58% |
| Dec 31, 23 | 1.01 B Decreased by -5.69% | 246.50 M Increased by +31.54% | Increased by +24.33% Increased by +39.47% |
| Sep 30, 23 | 945.30 M Decreased by -0.83% | 90.60 M Decreased by -23.67% | Increased by +9.58% Decreased by -23.04% |
| Jun 30, 23 | 984.40 M Decreased by -1.83% | -40.50 M Decreased by -117.73% | Decreased by -4.11% Decreased by -118.06% |
| Mar 31, 23 | 1.03 B Decreased by -28.50% | 218.50 M Decreased by -52.05% | Increased by +21.29% Decreased by -32.94% |
| Dec 31, 22 | 1.07 B Decreased by -26.98% | 187.40 M Decreased by -62.46% | Increased by +17.45% Decreased by -48.59% |